What are the consensus estimates for CALIDI BIOTHERAPEUTICS INC (CLDI) next earnings?
The consensus EPS estimate for the next earnings of CALIDI BIOTHERAPEUTICS INC (CLDI) is -1.63 USD and the consensus revenue estimate is 0 USD.
CALIDI BIOTHERAPEUTICS INC (CLDI) Forecast, Price Target & Analyst Ratings
NYSEARCA:CLDI • US3207034089
Current stock price
0.3181 USD
-0.01 (-3.78%)
At close:
0.315 USD
0 (-0.97%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CALIDI BIOTHERAPEUTICS INC (CLDI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$1.63
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.32 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
CLDI was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CLDI.
In the previous month the buy percentage consensus was at a similar level.
CLDI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-06-27 | Ladenburg Thalmann | Initiate | Buy |
| 2024-05-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-21 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-22 | HC Wainwright & Co. | Initiate | Buy |
| 2023-10-09 | Baird | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$1.63
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 73.40%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 449K | 45K -89.98% | -100.00% | 15.3M | 30.6M 100.00% | 63.24M 106.67% | |||||||
| EBITDA YoY % growth | -6.666M | -9.45M -41.76% | -22.868M -141.99% | N/A -25.07% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -6.773M | -9.606M -41.83% | -23.128M -140.77% | -27.13M -25.35% | -23.473M 19.04% | -21.883M 6.77% | -25.166M -15.00% | -28.94M -15.00% | -32.568M -12.53% | -22.437M 31.11% | -2.914M 87.01% | 17.434M 698.26% | |
| Operating Margin | N/A | -2,139.42% | -51,395.56% | N/A | N/A | N/A | N/A | N/A | N/A | -146.65% | -9.52% | 27.57% | |
| EPS YoY % growth | N/A | N/A | N/A | -171.36 | -45.25 68.07% | -7.59 86.13% | -5.68 25.16% | -4.90 13.79% | -3.55 27.50% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -1.63 73.40% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -5.854M -45.40% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A